Bailard’s Unity Biotechnology UBX Stock Holding History

Bailard’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,700	Closed	-$48.5K	–	792
2022 Q4	$48.5K	Buy	17,700 +12,600	+247%	+$36.6K	﹤0.01%	694
2022 Q3	$20K	Buy	+5,100	New	+$32.2K	﹤0.01%	660

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's UBX Position: Q1 2023 in Review

Bailard sold out of Unity Biotechnology (UBX) in Q1 2023, closing a stake of 17,700 shares — an estimated $48.5K sold.

Bailard first reported a position in UBX in Q3 2022 and held it in 2 quarters. The position peaked at $48.5K in Q4 2022. 46 funds tracked by Wall St. Rank hold UBX as of Q1 2023.

Bailard reported no remaining Unity Biotechnology position as of Q1 2023 after selling out during the quarter.
Bailard sold 17,700 Unity Biotechnology shares in Q1 2023, an estimated $48.5K.
Bailard first reported a position in Unity Biotechnology in Q3 2022 and held it in 2 quarters.
Bailard's Unity Biotechnology position peaked at $48.5K in Q4 2022.
46 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.